Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Study Number

2498022

Phase

I/II

Age Group

Adult

Principal Investigator

Steven Green

Purpose

SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.

Check your eligibility for this trial

Check now

Full Title

An Open-Label Phase 1A/1B Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPa-Fc-CD40L) in Combination With Azacitidine or with Azacitidine and Venetoclax for the Treatment of Subjects With Higher Risk Myelodysplastic Syndrome (MDS) or Acute…

ClinicalTrials.Gov ID

NCT05275439

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.